Report Sections

See All Reports

  • HP:0100526: Neoplasm of the lung
  • Pneumonia (361) Abnormality of the cardiovascular system (36) Respiratory tract infection (36) Neoplasm (29) Hypoxemia (28) Diabetes mellitus (25) Depressivity (24) Thromboembolism (23) Acute kidney injury (22) Abnormal lung morphology (21) Anosmia (19) Hypertension (18) Abnormality of coagulation (15) Pulmonary embolism (15) Pulmonary fibrosis (15) Stroke (14) Arthritis (14) Interstitial pneumonitis (14) Myocardial infarction (12) Type II diabetes mellitus (12) Deep venous thrombosis (11) Rheumatoid arthritis (10) Leukemia (10) Respiratory distress (10) Low levels of vitamin D (10) Behavioral abnormality (9) Mental deterioration (9) Chronic pain (9) Congestive heart failure (8) Myocarditis (8) Type I diabetes mellitus (8) Sepsis (8) Infertility (7) Abnormality of the liver (7) Lymphopenia (7) Inflammation of the large intestine (7) Pulmonary obstruction (7) Pulmonary insufficiency (7) Immunodeficiency (6) Systemic lupus erythematosus (6) Chronic pulmonary obstruction (6) Abnormality of the gastrointestinal tract (6) Neoplasm of the lung (6) Encephalopathy (5) Obesity (5) Lymphoma (5) Autoimmunity (5) Breast carcinoma (5) Disseminated intravascular coagulation (5) Fatigue (5) Abnormality of the kidney (4) Coronary artery atherosclerosis (4) Cardiac arrest (4) Headache (4) Colon cancer (4) Arrhythmia (4) Carcinoma (4) Hypercoagulability (4) Autistic behavior (3) Seizure (3) Cardiomyopathy (3) Dysphagia (3) Migraine (3) Pulmonary arterial hypertension (3) Asthma (3) Bronchiectasis (3) Neoplasm of the pancreas (3) Psoriasiform dermatitis (3) Attention deficit hyperactivity disorder (3) Cutaneous melanoma (3) Neoplasm of head and neck (3) Pulmonary edema (3) Insomnia (3) Neoplasm of the large intestine (3) Renal insufficiency (2) Hypogeusia (2) Hearing impairment (2) Abnormality of the eye (2) Visual impairment (2) Conjunctivitis (2) Psychosis (2) Autism (2) Dementia (2) Abnormality of the endocrine system (2) Abnormality of the thyroid gland (2) Jaundice (2) Hepatic fibrosis (2) Premature birth (2) Abnormal heart morphology (2) Abnormality of blood and blood-forming tissues (2) Fever (2) Diarrhea (2) Hypothermia (2) Neurodegeneration (2) Abnormal intestine morphology (2) Alopecia of scalp (2) Encephalitis (2) Obstructive sleep apnea (2) Male infertility (2) Stillbirth (2) Paroxysmal atrial fibrillation (2) Lymphoid leukemia (2) Myeloproliferative disorder (2) Chronic lymphatic leukemia (2) Renal cell carcinoma (2) Multiple myeloma (2) Abnormal anterior horn cell morphology (2) Amyotrophic lateral sclerosis (2) Sleep apnea (2) Cystoid macular edema (2) Hemeralopia (2) Arteritis (2) Chronic kidney disease (2) Cervix cancer (2) Cholangitis (2) Cholangiocarcinoma (2) Myositis (2) Neuroendocrine neoplasm (2) Neoplasm of the rectum (2) Mania (2) Nephritis (1) Menorrhagia (1) Conductive hearing impairment (1) Cataract (1) Amblyopia (1) Periodontitis (1) Abnormality of the nervous system (1) Oligospermia (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Abnormality of the skin (1) Lymphedema (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Spastic diplegia (1) Hemiparesis (1) Meningitis (1) Cerebral hemorrhage (1) Abnormal joint morphology (1) Hepatic failure (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Cor pulmonale (1) Tachycardia (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Angina pectoris (1) Pancreatitis (1) Premature rupture of membranes (1) Weight loss (1) Thrombocytopenia (1) Autoimmune thrombocytopenia (1) Gastroesophageal reflux (1) Anorexia (1) Esophageal varix (1) Apnea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Memory impairment (1) Difficulty walking (1) Hyperkinetic movements (1) Alzheimer disease (1) Increased intracranial pressure (1) Colitis (1) Biliary cirrhosis (1) Hypotension (1) Vascular dilatation (1) Atherosclerosis (1) Osteoarthritis (1) Tachypnea (1) Hypoventilation (1) Myelodysplasia (1) Neoplasm of the liver (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Reduced factor VIII activity (1) Skeletal muscle atrophy (1) Myalgia (1) Muscular dystrophy (1) Neonatal death (1) Increased body weight (1) Neoplasm of the nervous system (1) Malnutrition (1) Thrombophlebitis (1) Ventricular tachycardia (1) Acute myeloid leukemia (1) Dilatation of the cerebral artery (1) Knee osteoarthritis (1) Monoclonal immunoglobulin M proteinemia (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the stomach (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Renal neoplasm (1) Uterine neoplasm (1) Testicular neoplasm (1) Intestinal atresia (1) Tonsillitis (1) Inflammatory abnormality of the skin (1) Placental abruption (1) Postprandial hyperglycemia (1) Endometrial carcinoma (1) Erythroid hypoplasia (1) Asterixis (1) Glioblastoma multiforme (1) B-cell lymphoma (1) Ciliary dyskinesia (1) Morphea (1) Allergy (1) Non-Hodgkin lymphoma (1) Retinal vein occlusion (1) Heart block (1) Dyspareunia (1) Ductal carcinoma in situ (1) Endometriosis (1) Cardiogenic shock (1) Vulvar neoplasm (1) Addictive behavior (1) Femur fracture (1) Neonatal sepsis (1) Glue ear (1) Neoplasm of the central nervous system (1) Abnormality of movement (1) Ulcerative colitis (1) Crohn's disease (1) Endocarditis (1) Toxemia of pregnancy (1) Neoplasm of the larynx (1) Ovarian neoplasm (1) Vaginal neoplasm (1) Cellulitis (1) Bulimia (1) Atelectasis (1) Esophageal neoplasm (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0100526: Neoplasm of the lung

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (7)


    Name (Synonyms) Correlation
    drug1578 IgG test Wiki 0.41
    drug507 Breathing exercise, intensive spirometry use, supported cough, progressive mobilisation and ambulation Wiki 0.41
    drug765 Clinical Trial Matching Wiki 0.41
    Name (Synonyms) Correlation
    drug3977 questionnaire and optional interview Wiki 0.41
    drug1204 Exercise booklet Wiki 0.41
    drug1010 Diagnosis of SARS-Cov2 by RT-PCR and : IgG, Ig M serologies in the amniotoc fluid, the blood cord and the placenta Wiki 0.41
    drug610 COVID-19 convalescent plasma Wiki 0.18

    Correlated MeSH Terms (27)


    Name (Synonyms) Correlation
    D008175 Lung Neoplasms NIH 1.00
    D016889 Endometrial Neoplasms NIH 0.41
    D004938 Esophageal Neoplasms NIH 0.41
    Name (Synonyms) Correlation
    D013274 Stomach Neoplasms NIH 0.41
    D012878 Skin Neoplasms NIH 0.41
    D009423 Nervous System Neoplasms NIH 0.41
    D007680 Kidney Neoplasms NIH 0.41
    D016543 Central Nervous System Neoplasms NIH 0.41
    D005909 Glioblastoma NIH 0.41
    D008113 Liver Neoplasms NIH 0.41
    D007822 Laryngeal Neoplasms NIH 0.41
    D013736 Testicular Neoplasms NIH 0.41
    D002292 Carcinoma, Renal Cell NIH 0.29
    D002583 Uterine Cervical Neoplasms NIH 0.29
    D012004 Rectal Neoplasms NIH 0.29
    D018281 Cholangiocarcinoma NIH 0.29
    D018358 Neuroendocrine Tumors NIH 0.29
    D008545 Melanoma NIH 0.24
    D010190 Pancreatic Neoplasms NIH 0.24
    D006258 Head and Neck Neoplasms NIH 0.24
    D002277 Carcinoma NIH 0.20
    D003110 Colonic Neoplasms NIH 0.20
    D001943 Breast Neoplasms NIH 0.18
    D003141 Communicable Diseases NIH 0.03
    D007239 Infection NIH 0.02
    D045169 Severe Acute Respiratory Syndrome NIH 0.02
    D018352 Coronavirus Infections NIH 0.01

    Correlated HPO Terms (22)


    Name (Synonyms) Correlation
    HP:0002896 Neoplasm of the liver HPO 0.41
    HP:0008069 Neoplasm of the skin HPO 0.41
    HP:0012114 Endometrial carcinoma HPO 0.41
    Name (Synonyms) Correlation
    HP:0100006 Neoplasm of the central nervous system HPO 0.41
    HP:0010788 Testicular neoplasm HPO 0.41
    HP:0009726 Renal neoplasm HPO 0.41
    HP:0012174 Glioblastoma multiforme HPO 0.41
    HP:0100751 Esophageal neoplasm HPO 0.41
    HP:0004375 Neoplasm of the nervous system HPO 0.41
    HP:0006753 Neoplasm of the stomach HPO 0.41
    HP:0100605 Neoplasm of the larynx HPO 0.41
    HP:0005584 Renal cell carcinoma HPO 0.29
    HP:0100634 Neuroendocrine neoplasm HPO 0.29
    HP:0100743 Neoplasm of the rectum HPO 0.29
    HP:0030153 Cholangiocarcinoma HPO 0.29
    HP:0030079 Cervix cancer HPO 0.29
    HP:0002894 Neoplasm of the pancreas HPO 0.24
    HP:0012288 Neoplasm of head and neck HPO 0.24
    HP:0012056 Cutaneous melanoma HPO 0.24
    HP:0030731 Carcinoma HPO 0.20
    HP:0003003 Colon cancer HPO 0.20
    HP:0003002 Breast carcinoma HPO 0.18

    Clinical Trials

    Navigate: Correlations   HPO

    There are 6 clinical trials


    1 SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.

    NCT03452774
    Conditions
    1. Cancer, Metastatic
    2. Cancer
    3. Cancer of Pancreas
    4. Cancer of Liver
    5. Cancer of Stomach
    6. Cancer Liver
    7. Cancer of Rectum
    8. Cancer of Kidney
    9. Cancer of Esophagus
    10. Cancer of Cervix
    11. Cancer of Colon
    12. Cancer of Larynx
    13. Cancer, Lung
    14. Cancer, Breast
    15. Cancer, Advanced
    16. Cancer Prostate
    17. Cancer of Neck
    18. Cancer of Skin
    19. Neuroendocrine Tumors
    20. Carcinoma
    21. Mismatch Repair Deficiency
    22. BRCA Gene Rearrangement
    23. Non Hodgkin Lymphoma
    24. Leukemia
    25. Non Small Cell Lung Cancer
    26. Cholangiocarcinoma
    27. Glioblastoma
    28. Central Nervous System Tumor
    29. Melanoma
    30. Urothelial Carcinoma
    31. Bladder Cancer
    32. Ovarian Cancer
    33. Endometrial Cancer
    34. Testicular Cancer
    35. Breast Cancer
    36. COVID
    Interventions
    1. Other: Clinical Trial Matching
    MeSH:Carcinoma Glioblastoma Endometrial Neoplasms Neuroendocrine Tumors Cholangiocarcinoma Nervous System Neoplasms Central Nervous System Neoplasms Testicular Neoplasms Pancreatic Neoplasms Breast Neoplasms Lung Neoplasms Esophageal Neoplasms Stomach Neoplasms Liver Neoplasms Colonic Neoplasms Uterine Cervical Neoplasms Rectal Neoplasms Kidney Neoplasms Carcinoma, Renal Cell Skin Neoplasms Head and Neck Neoplasms Laryngeal Neoplasms
    HPO:Breast carcinoma Carcinoma Cervical polyp Cervix cancer Cholangiocarcinoma Clear cell renal cell carcinoma Colon cancer Endometrial carcinoma Esophageal neoplasm Glioblastoma multiforme Neoplasm of head and neck Neoplasm of the breast Neoplasm of the central nervous system Neoplasm of the colon Neoplasm of the larynx Neoplasm of the liver Neoplasm of the lung Neoplasm of the nervous system Neoplasm of the pancreas Neoplasm of the rectum Neoplasm of the skin Neoplasm of the stomach Neuroendocrine neoplasm Papillary renal cell carcinoma Renal cell carcinoma Renal neoplasm Testicular neoplasm

    Primary Outcomes

    Description: CTE Accrual

    Measure: Proportion of patients Eligible for CTE versus Actual CTE

    Time: Through study completion, an average of 1 year

    Secondary Outcomes

    Description: OS

    Measure: Impact of CTE on Overall Survival (OS), estimated by Kaplan-Meier and Cox multivariable survival analysis

    Time: 4 years

    Description: PFS

    Measure: Impact of CTE on Progression-Free Survival (PFS), estimated by Kaplan-Meier and Cox multivariable survival analysis

    Time: 4 years

    Description: To identify barriers to accruals to clinical trials, as measured and reported by a questionnaire

    Measure: Identification of Barriers to CTE

    Time: Through study completion, an average of 1 year

    Description: To Analyze Individual Standard of Care Chemotherapy Utilization (nominal), across treatment lines (numeric); data will be combined and aggregated to report chemotherapy utilization rate (%).

    Measure: Real World Data Analytics

    Time: Through study completion, an average of 1 year

    Description: VTB Use Rate

    Measure: Virtual Tumor Board Utilization

    Time: Through study completion, an average of 1 year

    Description: Time to CTE

    Measure: Time from Intervention to Actual CTE (months)

    Time: Through study completion, an average of 1 year
    2 Observational Retrospective Register of Spanish Lung and Melanoma Cancer Patients With COVID19 Disease

    This is a multi-centre study on lung cancer patients which experienced COVID-19. Information on clinical features, clinical course, management and outcomes will be collected for both, thoracic cancers and COVID-19 infection. Firstly, investigators will be registered in an online secure registry. After that, a protocol will be developed in order to collect clinical data for the research. It will also include I on the care organization or the perception of the patient and their family members. The final stage will consist on retrospective data collection from patients. So, it is a retrospective study data collection, preceded by prospective data registry.

    NCT04344002
    Conditions
    1. Covid-19
    2. Lung Cancer
    MeSH:Lung Neoplasms Melanoma
    HPO:Cutaneous melanoma Melanoma Neoplasm of the lung

    Primary Outcomes

    Description: Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as clinical data.

    Measure: Clinical data of lung cancer patients with COVID-19 diagnoses

    Time: From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 years

    Description: Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as data about diagnosis

    Measure: Diagnosis data

    Time: From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 years

    Description: Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as treatments received

    Measure: Treatments received

    Time: From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 years

    Description: Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as prognostic factors.

    Measure: Prognostic factors

    Time: From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 years
    3 Impact of Confinement and Preventive Measures in Period of SARS-COV2 Infection on Clinical Features, Diagnostic and Therapeutic Management and Prognosis of Patients With Lung Cancer: an Ambispective Study Extended Over 2 Time Periods.

    The unexpected onset of SARS-COV2 infection modified our practices, especially in routine medicine. In order to reverse the epidemic curve of severe cases and slow the spread of the infection, confinement was generalized in France from March 13, 2020.These restrictive measures were imposed on anyone with symptoms compatible with the infection, with the exception of dyspnea and other criteria of severity. March 12, 2020 is the pivotal date when the management of COVID came to interfere with medical and healthcare organizations. From this date, it is likely that some imaging or endoscopic exams have been de-scheduled for symptoms that are sometimes wrongly judged to be non-urgent and have seen their numbers drop dramatically.Otherwise, concerning lung cancer, preventive measures have been extremely strengthened. For instance, it is recommended to delay surgeries for localized tumors, to relieve or remove some chemotherapy or to delete radiotherapy sessions deemed non-essential. However, symptoms that may initially be attributed to viral infection, such as cough, fever, fatigue, or chest pain may be clinical indicators of early-stage Lung cancer. In addition, lung cancer is likely to make the patient more susceptible to pneumopathy, due to a weakened of immune response to viruses and bacteria. Consequently, as necessary as the restriction measures are, a risk of slowing down in the management of the Lung cancer pathology exists. The CBP-COVID Study intends to assess consequences of restrictive measures linked to the SARS-COV2 epidemic, by comparing clinical characteristics at diagnosis, treatment times and treatments, regarding to 2 distinct time periods identical to the calendar, but one in 2019, the other in 2020.

    NCT04366219
    Conditions
    1. COVID
    2. SARS-CoV 2
    3. Lung Cancer
    MeSH:Lung Neoplasms
    HPO:Neoplasm of the lung

    Primary Outcomes

    Description: Comparison Group 2019 versus Group 2019

    Measure: Comparison of clinical characteristics

    Time: At the end of the second period, i.e. on August 28, 2020

    Secondary Outcomes

    Description: Comparison Group 2019 versus Group 2020

    Measure: Comparison of diagnostic procedures

    Time: At the end of the second period, i.e. on August 28, 2020

    Description: Comparison Group 2019 versus Group 2020

    Measure: Comparison of treatments (according to stage of disease)

    Time: At the end of the second period, i.e. on August 28, 2020

    Description: Comparison Group 2019 versus Group 2020

    Measure: Comparison of patients management deadlines

    Time: At the end of the second period, i.e. on August 28, 2020

    Description: Comparison Group 2019 versus Group 2020

    Measure: Comparison of survival

    Time: After 2 years post diagnoses
    4 Study of Acquired Immunity in Patients With Lung Cancer and COVID-19 Infection

    Observational, retrospective data collection and prospective IgG analysis, and multicenter study. The main objective of the study is th description of the characteristics and evolution of patients with lung cancer who have acquired COVID-19 infection. For the identification of patients who contract COVID-19 infection, the IgG+ blood test by ELISA method will be used.

    NCT04407143
    Conditions
    1. Lung Cancer
    2. COVID
    3. Corona Virus Infection
    Interventions
    1. Diagnostic Test: IgG test
    MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome Lung Neoplasms
    HPO:Neoplasm of the lung

    Primary Outcomes

    Description: Description of the characteristics and evolution of patients with lung cancer who have contracted COVID-19 infection.

    Measure: Description of the characteristics of patients

    Time: From the diagnosis of the COVID until the determination of the blood IgGs, up to 10 weeks
    5 Understanding the Physical, Social and Psychological Impact of COVID-19 on Frail and Shielded Lung Cancer Patients

    During the COVID-19 pandemic, people's lives have changed dramatically. People with lung cancer who are shielding may have been particularly affected as they may be unable to carry out many of their normal daily activities, such as grocery shopping and exercise, and are unable to interact with friends and family. People with lung cancer will also have experienced some changes to the clinical services available to them at The Christie. Using a questionnaire and interviews, the investigators want to understand patient experiences of the changes in their daily lives and the changes to their clinical care. This will help us to see if people with lung cancer need any additional support services or if there are any changes the investigators can make to clinical services to improve patient experiences. Eligible patients will be any lung cancer patients receiving current treatment or in active follow up.

    NCT04538456
    Conditions
    1. Lung Cancer
    2. PROM
    3. Covid19
    4. Psychological
    Interventions
    1. Other: questionnaire and optional interview
    MeSH:Lung Neoplasms
    HPO:Neoplasm of the lung

    Primary Outcomes

    Description: Physical and social impact will be captured by the EuroQual-5D quality of life and questions regarding patient's diagnosis and treatment pathway including a list of symptoms based on the Common Terminology Criteria for Adverse Events.

    Measure: Physical and Social impact

    Time: baseline

    Description: Emotional impact will be assessed using the Hospital Anxiety Depression Scale. Scores range from 0-21 for each of the two subscales (anxiety and depression), with higher scores indicating greater anxiety and depression.

    Measure: Psychological impact

    Time: baseline

    Secondary Outcomes

    Description: Frailty will be assessed using the Rockwood Clinical Frailty Scale. With scores ranging from 1-9, with higher scores indicating higher frailty.

    Measure: prevalence and impact of frailty

    Time: baseline
    6 Telerehabilitation of Reduced Physiotherapy Service in SARS-CoV-2 Pandemic Process in Lung Surgery Patients

    In this study, providing access to physiotherapy applications by telerehabilitation method and the effectiveness of this application will be examined for patients who have undergone lung surgery in the early postoperative period during the pandemic process in which social isolation continues.

    NCT04568564
    Conditions
    1. Lung Cancer
    2. Physiotherapy
    Interventions
    1. Other: Breathing exercise, intensive spirometry use, supported cough, progressive mobilisation and ambulation
    2. Other: Exercise booklet
    MeSH:Lung Neoplasms
    HPO:Neoplasm of the lung

    Primary Outcomes

    Description: Major complication rates such as postoperative fever, infection, and hemorrhage will be documented.

    Measure: Major complication rate

    Time: Up to 3 months

    Secondary Outcomes

    Description: The six-minute walking test is an example of timed distance testing, widely used in clinical research and rehabilitation studies. According to the guidelines published by the American Thoracic Society, 6MWT is an easy-to-use, better tolerated test that reflects daily activities better than other walking tests. It can be applied in a short time. Requires little equipment. The six-minute walk test, used as a field test, is a simple and inexpensive test compatible with daily activities, which does not require exercise equipment. Before starting the test, the patient should rest for at least 10 minutes by sitting in the chair near the starting point. The walking area must be at least 30 m long. A shorter corridor causes more time to be spent for more frequent turns and changes of direction. With the help of stopwatch, it is kept for 6 minutes and the number of laps during the period is calculated and recorded. The functional capacity of the cases will be evaluated with 6MWT.

    Measure: The six-minute walking test

    Time: Up to 3 months

    Description: It is a scale used to determine the severity of dyspnea with a rating of zero to 4. Zero means no dyspnea perception and 4 means severe dyspnea.

    Measure: Modified Medical Research Council Dyspnea Scale

    Time: Up to 3 months

    Description: The pain, dyspnea and fatigue level of the cases were evaluated with visual analog scale (VAS) score. The scale presented as a 100 mm horizontal ruler is a documented method for scoring continuous soft data. "0" score means no pain, "100" means very severe pain

    Measure: Visual analog scale

    Time: Up to 3 months

    Measure: Duration of tube thoracostomy drainage

    Time: Up to 3 months

    Description: FEV1 measurements will be reported as absolute values (e.g. liters, measured) and percentage of predicted (FEV1measured/ FEV1 predicted).

    Measure: Forced expiratory volume one second (FEV1)

    Time: Up to 3 months

    Description: FVC measurements will be reported as absolute values (e.g. liters, measured) and percentage of predicted (FVCmeasured/ FVC predicted).

    Measure: Forced vital capacity (FVC)

    Time: Up to 3 months

    Description: DLCO and DLCO / VA values will be analyzed

    Measure: Diffusion Capacity

    Time: Change from baseline to 1 and 3 months

    Description: Lung capacities will be given the measured value and their percentages will be calculated according to the estimated values.

    Measure: Lung Capacities

    Time: Change from baseline to 1 and 3 months

    Description: Tumor side and contralateral lung V / Q scintigraphy measurements will be made.

    Measure: Lung V/Q Scintigraphy

    Time: Change from baseline to 1 and 3 months

    Description: Procalcitonin is a substance produced by many types of cells in the body, often in response to bacterial infections but also in response to tissue injury. The level of procalcitonin in the blood can increase significantly in systemic bacterial infections and sepsis.The reference value of PCT in adults and children older than 72 hours is 0. 15 ng/mL or less.

    Measure: Procalcitonin (PCT)

    Time: Up to 3 months

    Description: C-reactive protein is a substance produced by the liver in response to inflammation. For a standard CRP test, a normal reading is less than 10 milligram per liter (mg/L). A test result showing a CRP level greater than 10 mg/L is a sign of serious infection, trauma or chronic disease, which likely will require further testing to determine the cause

    Measure: C-Reactive Protein (CRP)

    Time: Up to 3 months

    Description: Ferritin is a blood protein that contains iron. The normal ferritin levels range from 12 to 300 nanograms per milliliter of blood (ng/mL) for males and 12 to 150 ng/mL for females.

    Measure: Ferritin

    Time: Up to 3 months

    Description: Lactate dehydrogenase is an enzyme that helps turn sugar into energy for your cells. High LDH levels could indicate cell damage.Normal LDH levels range from 140 units per liter (U/L) to 280 U/L or 2.34 microkatals/L to 4.68 microkatals/L.

    Measure: Lactate dehydrogenase

    Time: Up to 3 months

    Description: D-dimer tests are used to help rule out the presence of an inappropriate blood clot (thrombus). The reference concentration of D-dimer is < 250 ng/mL, or < 0.4 mcg/mL.

    Measure: D'dimer test

    Time: Up to 3 months

    Description: The partial pressure of carbon dioxide (PCO2) is the measure of carbon dioxide within arterial or venous blood. It often serves as a marker of sufficient alveolar ventilation within the lungs. Generally, under normal physiologic conditions, the value of PCO2 ranges between 35 to 45 mmHg.

    Measure: Partial Carbon monoxide Pressure (PaCO2)

    Time: Up to 3 months

    Description: The partial pressure of oxygen, also known as PaO2, is a measurement of oxygen pressure in arterial blood. 75 to 100 millimeters of mercury (mm Hg) is the normal ranges.

    Measure: Partial Oxigen Pressure (PaO2)

    Time: Up to 3 months

    Description: It reflects the saturation level of hemoglobin with oxygen. Its normal values are 95-100%.

    Measure: Arterial blood oxygen saturation level (SaO2)

    Time: Up to 3 months

    Description: The state-trait anxiety scale will determine the anxiety levels of patients before and after surgery. It is a psychological inventory based on a 4-point Likert scale and consists of 40 questions on a self-report basis. The STAI measures two types of anxiety - state anxiety, or anxiety about an event, and trait anxiety, or anxiety level as a personal characteristic.While evaluating, a score between 1 (or -1) and 4 (or -4) is given for each item according to the positive or negative characteristics of the item, and the total score to be obtained is 50 constant is added. The highest score is 80, the lowest is 20. Total anxiety the higher the score, the more anxiety level of the person filling the scale.

    Measure: Anxiety inventory

    Time: Up to 3 months

    HPO Nodes


    Reports

    Data processed on December 13, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,818 reports on interventions/drugs

    MeSH

    706 reports on MeSH terms

    HPO

    306 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook